High-Risk Companion Diagnostics Need IDEs Prior To Drug Trial, FDA Says
Executive Summary
Companies planning to co-develop an in vitro companion diagnostic alongside a therapeutic should be certain that the assay has been analytically validated and, if high risk, has won investigational device exemption before the drug trial begins, FDA warns in a July 14 draft guidance.
You may also be interested in...
Companion Diagnostics Guidance Finalized, But LDT Context Will Be Key
FDA has finalized its guidance on companion diagnostics with very few revisions from the draft it released three years ago. But the final guidance was released simultaneously with FDA’s much-delayed proposal to begin actively regulating lab-developed tests, which presents important underlying questions for companion diagnostic policy.
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.
HHS Secretary Nominee Becerra Commits To Telehealth Expansion, Procedure Price Transparency
At two recent confirmation hearings, HHS secretary nominee Xavier Becerra promised Senators he would help expand telehealth and procedure price transparency.